Neumedicines Inc. Awarded BAA-BARDA-08-08 Contract by the Biomedical Advanced Research and Development Authority (BARDA)
Contract for The Development of a Therapeutic Solution for the Hematopoietic Syndrome Resulting from Exposure to Acute Ionizing Radiation
Washington D.C. & Pasadena, CA – September 16, 2008 – Today BARDA announced the award of Contract BAA-BARDA-08-08 to Neumedicines Inc. for the development of a therapeutic solution for the hematopoietic syndrome resulting from exposure to acute ionizing radiation.
The therapeutic under development by Neumedicines Inc., HemaMax™, is based on rHuIL-12 (Recombinant Human Interleukin – 12). Scientists from Neumedicines Inc. discovered the previously unknown hematological properties of IL-12 by demonstrating the potent survival effects of single, low dose IL-12 on hematopoietic recovery following lethal radiation.
"We are excited to begin work under this contract, which is directly aligned with our ongoing research and product development efforts over the past five years. Says Lena A. Basile, Ph.D., J.D. – President & Director of Research & Development of Neumedicines Inc. “The application of HemaMax™ to treat human hematopoietic syndrome resulting from radiation exposure represents an extremely important medical advance that promises to offer an effective treatment for an otherwise fatal radiation injury."
HemaMax™ is a new therapeutic which is based on IL-12 and administered in low doses to achieve potent radiomitigation effects. Neumedicines Inc. has to date proven to increase survivability by 90% in mice administered HemaMax™ in single, low doses 24 hours after lethal radiation exposure.
The BAA-BARDA-08-08 contract awarded to Neumedicines Inc. is represented by a base year of funding with two additional option years that can be awarded based on contract developmental milestones and performance. The total contract award including the base contract and options is projected to yield over $13M for the development of HemaMax™ as a radiomitigator. Performance under the BARDA contract is expected to fund research and development culminating in a first-in-man Phase I clinical trial for HemaMax™.
About BARDA - The Biomedical Advanced Research and Development Authority (BARDA), within the Office of the Assistant Secretary for Preparedness and Response in the U.S. Department of Health and Human Services, provides an integrated, systematic approach to the development and purchase of the necessary vaccines, drugs, therapies, and diagnostic tools for public health medical emergencies.
BARDA manages Project BioShield, which includes the procurement and advanced development of medical countermeasures for chemical, biological, radiological, and nuclear agents, as well as the advanced development and procurement of medical countermeasures for pandemic influenza and other emerging infectious diseases that fall outside the auspices of Project BioShield. In addition, BARDA manages the Public Health Emergency Countermeasures Enterprise (PHEMCE).
Neumedicines, Inc. was founded in 2003 as a start-up company from the University of Southern California (USC) and is exclusively engaged in research and development of both prophylactics and therapeutics based on Interleukin-12 (IL-12) (HemaMax™), for the mitigation and reversal of radiological (myeloablative) and myelosuppressive effects on the human hematopoietic system. In animal tumor models, HemaMax™ has been shown to be effective in restoring hematopoiesis following either radiation or chemotherapy. Thus, clinical applications for HemaMax™ are also being pursued in hematology and oncology.
Richard Leon, Director of Communications